Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Oral Squamous Cell Carcinoma · Neoadjvant Therapy · Anti-PD-1 · Chemotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Lai-ping Zhong, MD, PhD) · zhonglaiping@163.com · +86-21-23271699
Contact: Principal Investigator (Lai-ping Zhong, MD, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma · Neoadjvant Therapy · Anti-PD-1

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Oral Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Recurrent Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Duarte, United States · Miami, United States

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Locally Advanced Oral Squamous Cell Carcinoma · Oral Squamous Cell Carcinoma (OSCC)

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China